View Post

Clinical Challenges: HR+/HER2- Advanced Breast Cancer and CDK4/6 Inhibitors

In Clinical Studies News by Barbara Jacoby

By: Mike Bassett From: The agents have significantly extended progression-free survival, but what are the options post-progression? The development and approval of cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors have been called game-changers in the treatment of patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer. Treatment with these drugs — palbociclib, ribociclib, …